<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10789721</article-id><article-id pub-id-type="pmc">2363396</article-id><article-id pub-id-type="pii">6691175</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1175</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vahrmeijer</surname><given-names>A L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>van Dierendonck</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Keizer</surname><given-names>H J</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Beijnen</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tollenaar</surname><given-names>R A E M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pijl</surname><given-names>M E J</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Marinelli</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kuppen</surname><given-names>P J K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>van Bockel</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mulder</surname><given-names>G J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Velde</surname><given-names>C J H van de</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Departments of Surgery, <label>2</label>Clinical Oncology, <label>3</label>Radiology, Leiden University Medical Center, PO Box 9600, Leiden, RC 2300, The Netherlands</aff><aff id="aff4"><label>4</label>Division of Toxicology, Leiden/Amsterdam Center for Drug Research, PO Box 9503, Leiden, RA 2300, The Netherlands</aff><aff id="aff5"><label>5</label>Faculty of Pharmacy, University Utrecht, Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, Amsterdam, EC 1066, The Netherlands</aff><pub-date pub-type="epub"><day>03</day><month>04</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>05</month><year>2000</year></pub-date><volume>82</volume><issue>9</issue><fpage>1539</fpage><lpage>1546</lpage><history><date date-type="received"><day>28</day><month>07</month><year>1999</year></date><date date-type="rev-recd"><day>10</day><month>01</month><year>2000</year></date><date date-type="accepted"><day>25</day><month>01</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>A phase I dose-escalation study was performed to determine whether isolated hepatic perfusion (IHP) with melphalan (L-PAM) allows exposure of the liver to much higher drug concentrations than clinically achievable after systemic administration and leads to higher tumour concentrations of L-PAM. Twenty-four patients with colorectal cancer confined to the liver were treated with L-PAM dosages escalating from 0.5 to 4.0 mg kg<sup>&#x02212;1</sup>. During all IHP procedures, leakage of perfusate was monitored. Duration of IHP was aimed at 60 min, but was shortened in eight cases as a result of leakage from the isolated circuit. From these, three patients developed WHO grade 3&#x02013;4 leukopenia and two patients died due to sepsis. A reversible elevation of liver enzymes and bilirubin was seen in the majority of patients. Only one patient was treated with 4.0 mg kg<sup>&#x02212;1</sup>L-PAM, who died 8 days after IHP as a result of multiple-organ failure. A statistically significant correlation was found between the dose of L-PAM, peak L-PAM concentrations in perfusate (R = 0.86, <italic>P</italic>&#x02264; 0.001), perfusate area under the concentration-time curve (AUC; R = 0.82, <italic>P</italic>&#x0003c; 0.001), tumour tissue concentrations of L-PAM (R = 0.83, <italic>P</italic> = 0.011) and patient survival (R = 0.52, <italic>P</italic> = 0.02). The peak L-PAM concentration and AUC of L-PAM in perfusate at dose level 3.0 mg kg<sup>&#x02212;1</sup>(<italic>n</italic> = 5) were respectively 35- and 13-fold higher than in the systemic circulation, and respectively 30- and 5-fold higher than reported for high dose oral L-PAM (80&#x02013;157 mg m<sup>&#x02212;2</sup>) and autologous bone marrow transplantation. Median survival after IHP (<italic>n</italic> = 21) was 19 months and the overall response rate was 29&#x00025; (17 assessable patients; one complete and four partial remissions). Thus, the maximally tolerated dose of L-PAM delivered via IHP is approximately 3.0 mg kg<sup>&#x02212;1</sup>, leading to high L-PAM concentrations at the target side. Because of the complexity of this treatment modality, IHP has at present no place in routine clinical practice. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>isolated hepatic perfusion</kwd><kwd>melphalan</kwd><kwd>colorectal cancer</kwd><kwd>liver metastases</kwd></kwd-group></article-meta></front></article>


